Navigation Links
Dendreon Receives FDA Acknowledgement of Complete Response
Date:11/20/2009

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

The FDA considers this to be a complete, Class 2 Resubmission following the action letter the company received in 2007. The BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. The resubmission also contains the remaining information requested by the FDA pertaining to chemistry, manufacturing and controls section of the BLA for PROVENGE.

If approved by the FDA, PROVENGE would represent the first product in a new therapeutic class known as active cellular immunotherapies.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple ty
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
2. Dendreon Completes Submission of Biologics License Application for PROVENGE
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
6. Dendreon Reports Second Quarter 2009 Financial Results
7. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
8. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
11. Dendreon Announces Closing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Its that time again for the half-year roundup of stock market ... you recall the results from the first quarter, it was pretty ... percent , Nasdaq National Market down 8 percent , Nasdaq Biotech ... isnt a great trend. As you can see below, the results ...
... International, a supplier of automatic identification and data collection ... 4.0 of their NiceLabel software. , ,The new versions ... radio frequency identification (RFID) tags, as well as an ... with Windows programs such as Microsoft Access, Windows Event ...
... As NASA works to get the Space Shuttle Discovery ... be monitored by NASA flight surgeons using GE Healthcare's ... health information will enable NASA to monitor and track the ... the sharing also of information with experts located outside NASA's ...
Cached Biology Technology:Midwest large cap life sciences mostly outperform market 2Midwest large cap life sciences mostly outperform market 3
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the wind, but a new study in the October 14th ... confirms that they are anything but drifters. A previous ... evidence that Silver Y moths rely on a sophisticated internal ... destination within a matter of days. Now, the research team ...
... mouse heart has an astounding capacity to regenerate, ... The research, published by Cell Press in the ... Cell , describes the previously unrecognized potential of ... compensatory proliferation of healthy cells. Disorders of ...
... why people who eat more fruit and vegetables may gain ... that a fragment released from pectin, found in all fruits ... 3 (Gal3), a protein that plays a role in all ... effects of foods are based on population studies," says Professor ...
Cached Biology News:Migratory moths may hitch their rides, but they're anything but drifters 2Embryonic heart exhibits impressive regenerative capacity 2Pectin power 2
...
Red Standard is sodium salt of resorufin....
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: